EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC0

Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea

Jannet A Tobon Ramos iD, Tobias Maure, Lenore Carias, Daphne Lew, Charles Goss, Anna Samuel, Livingstone Tavul, Peter U Fischer, Gary J Weil, Moses Laman, Leanne J Robinson, William Pomat und 1 weitere

PLOS Neglected Tropical Diseases · 2025

DOI: 10.1371/journal.pntd.0012851 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift PLOS Neglected Tropical Diseases, 2025. Verfasst von Jannet A Tobon Ramos und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, United States of America. Hauptthemen laut MEDLINE: Anthelmintics, Elephantiasis, Filarial, Hookworm Infections, Ivermectin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NCATS NIH HHS, Bill and Melinda Gates Foundation, National Health and Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Persons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended by WHO for mass drug administration (MDA) for LF instead of diethylcarbamazine/albendazole (DA) in Papua New Guinea (PNG). We compared the effectiveness of a single round of MDA with IDA or DA on hookworm and strongyloidiasis in PNG. Methodology/Principal Findings This study was conducted as part of a cluster randomized trial of MDA with IDA versus DA for LF in individuals willing to provide stool and blood samples at baseline and 12 months after MDA. Participants from 23 villages were included in the clinical trial. Primary outcomes were changes in hookworm prevalence and infection intensity assessed by Kato Katz and Strongyloides prevalence by serology. Hookworm prevalence at baseline was 78% (91/117) and 80% (119/149) in villages assigned to DA and IDA treatment, respectively. Twelve months post-MDA, hookworm prevalence decreased to 56.5% in DA- and 34.4% in IDA-treated villages, respectively ( p 2000 egg per gram (EPG)) similarly decreased from 8.7% to 1.5% after DA ( p = 0.001) and from 5.7% to 1.0% after IDA ( p = 0.002). Using a logistic regression model adjusting for age, gender, baseline hookworm prevalence, and village drug coverage, IDA resulted in a 45% greater reduction in hookworm prevalence than DA (Odds ratio 0.55, 95% CI [0.31,0.99], p = 0.049). MDA also reduced hookworm transmission. Strongyloides seroprevalence at baseline was 68% (192/283) and 62% (180/290) in IDA and DA villages, respectively, with 49% becoming seronegative in the IDA versus 23% in DA villages at 12 months ( p = 0.0001). Conclusions/Significance MDA with IDA was more effective than DA for reducing hookworm and Strongyloides infections in PNG, extending the benefit of MDA with IDA beyond its effect on LF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnthelminticsElephantiasis, FilarialHookworm InfectionsIvermectinMass Drug AdministrationStrongyloidiasisAdolescentAdultAgedAnimalsChildChild, PreschoolFemaleHumansMaleMiddle AgedYoung AdultAlbendazoleAncylostomatoideaDiethylcarbamazinePapua New GuineaPrevalenceStrongyloides stercoralisTreatment Outcome

Substanzen

AlbendazoleAnthelminticsDiethylcarbamazineIvermectin

Autor:innen und Institutionen

  • Department of Pathology, Center for Global Health and Diseases, Case Western Reserve University, Cleveland, Ohio, United States of America.
  • Department of Infection and Immunity, Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
  • Institute for Informatics, Data Science, and Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Department of Health Science and Epidemiology, Burnet Institute, Melbourne, Victoria, Australia.
  • Medical Services, Veterans Affairs Medical Center, Cleveland, Ohio, United States of America.

ORCID-Profile: Jannet A Tobon Ramos

Förderung

  • NCATS NIH HHS
  • Bill and Melinda Gates Foundation
  • National Health and Medical Research Council

Zitieren

APA

Tobon Ramos, J. A., Maure, T., Carias, L., Lew, D., Goss, C., Samuel, A., Tavul, L., Fischer, P. U., Weil, G. J., Laman, M., Robinson, L. J., Pomat, W., & King, C. L. (2025). Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012851

Vancouver

Tobon Ramos JA, Maure T, Carias L, Lew D, Goss C, Samuel A, et al. Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea. PLOS Neglected Tropical Diseases. 2025. doi:10.1371/journal.pntd.0012851

BibTeX
@article{TobonRamos2025,
  author = {Tobon Ramos, Jannet A and Maure, Tobias and Carias, Lenore and Lew, Daphne and Goss, Charles and Samuel, Anna and Tavul, Livingstone and Fischer, Peter U and Weil, Gary J and Laman, Moses and Robinson, Leanne J and Pomat, William and King, Christopher L},
  title = {Impact of mass drug administration with ivermectin, diethylcarbamazine, and albendazole for lymphatic filariasis on hookworm and Strongyloides stercoralis infections in Papua New Guinea},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2025},
  doi = {10.1371/journal.pntd.0012851}
}
Kostenlos starten →